Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Veers From Guidance In Some Supplement Health Claim Decisions – Court

This article was originally published in The Tan Sheet

Executive Summary

FDA made unreasonable demands with disclaimers for proposed qualified health claims for vitamin C and vitamin E to reduce the risk of cancer, according to a court ruling.

You may also be interested in...



Ruling Against Cigarette Warnings Could Impact Other FDA Labeling

A judge’s opinion that requiring graphic images on cigarette packages unconstitutionally compels speech could affect FDA’s qualifications for supplement health claims and its off-label rules. FDA “carries the burden of proving” the required speech is truthful and accurate, says attorney Jonathan Emord.

Ruling Against Cigarette Warnings Could Impact Other FDA Labeling

A judge’s opinion that requiring graphic images on cigarette packages unconstitutionally compels speech could affect FDA’s qualifications for supplement health claims and its off-label rules. FDA “carries the burden of proving” the required speech is truthful and accurate, says attorney Jonathan Emord.

FDA Has Authority To Be Vague On Supplement GMP Standards, Court Rules

FDA can set somewhat vague standards for dietary supplement firms' compliance with some good manufacturing practice regulations, according to a ruling in a complaint challenging the agency's authority to issue GMP requirements.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel